Dr. Saloni Satish Wagh
#709Managing Director
33
Age
16y
Exp
16y
Tenure
6/10
Risk
🎓 B.Sc in Science · Sathaye College, University of Mumbai
📜 Ph.D in Chemistry · Pacific University, Udaipur
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
6
Agre
4
Neur
Supriya Lifesci.
Healthcare · Small Cap
High Growth · Founder-Centric
About
Dr. Saloni Satish Wagh is the Managing Director of Supriya Lifesci., a Small Cap company in the Healthcare sector with a market cap of ₹5K Cr. A Transformational leader with 16 years of experience, she is known for consensus-driven decision-making and organic builder strategy. Her recent leadership initiatives emphasize expanding the company's R&D capabilities and diversifying the API product portfolio.
FAQ
What is Dr. Saloni Satish Wagh's leadership style?
Dr. Saloni Satish Wagh is classified as a Transformational leader. She is consensus-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Dr. Saloni Satish Wagh's educational background?
Dr. Saloni Satish Wagh holds a B.Sc in Science from Sathaye College, University of Mumbai and a Ph.D in Chemistry from Pacific University, Udaipur.
Who is the CEO of Supriya Lifesci.?
Dr. Saloni Satish Wagh is the Managing Director of Supriya Lifesci.. She has been with the company for 16 years and in the current role for 1 years.
Leadership DNA
ArchetypeTransformational
MotivationCategory Creator
CrisisSteady Hand
DecisionConsensus-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerSteady Employer
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Her recent leadership initiatives emphasize expanding the company's R&D capabilities and diversifying the API product portfolio.”
⚡ Crisis●●●○○
During the pandemic, Wagh focused on maintaining supply chain continuity and regulatory compliance for essential API production rather than aggressive restructuring.
🎯 Motivation●●●○○
She has pivoted Supriya Lifescience toward niche, high-barrier-to-entry therapeutic segments like anesthetics and vitamins to define a specialized market position.
👥 People●●●○○
As a second-generation leader, she emphasizes maintaining the core values and long-term stability of the family-founded organization while fostering internal consensus.
📈 Growth●●●●○
Supriya Lifescience's growth has been primarily driven by capacity expansion at their Lote Parshuram facility and increasing the depth of their existing product portfolio.
💡 Innovation●●●●○
The company focuses on expanding its portfolio of niche Active Pharmaceutical Ingredients (APIs) and intermediates by leveraging process chemistry expertise to enter established high-value markets.
🏃 Pace●●●●○
The business follows a methodical approach to capacity expansion and regulatory filings, typical of a mid-to-small cap API manufacturer scaling operations incrementally.
🌱 Purpose●●●○○
The company operates primarily as a B2B manufacturer focused on scaling production and export volumes, with CSR activities limited to statutory compliance requirements.
🏷️ Brand●●●●○
The company is recognized for its technical proficiency in complex chemistry and its ability to maintain high-standard manufacturing facilities for global pharmaceutical clients.
🤝 Customer●●●●●
Supriya Lifescience is a specialized API manufacturer that supplies pharmaceutical formulations to global regulated and semi-regulated markets through B2B contracts.
💼 Employer●●●○○
As a manufacturing-heavy organization in the API sector, it provides a stable, process-oriented work environment focused on operational consistency and quality compliance.
📋 Mandate
Scaling API manufacturing footprint globally requires strategic investments in R&D and geographic market penetration.
🏢 Culture●●●○○
The company maintains a high promoter control with the MD directly involved in steering the R&D and manufacturing trajectory.
Financials
Revenue FY25₹680 Cr
PAT FY25₹188 Cr
Rev CAGR 5Y9.4%
OPM34.7%
NPM27.7%
ROE18.9%
ROCE22.9%
P/E25.1
Fwd P/E18.8
P/B4.3
D/E0.5
Promoter70.8%
Institutional3.8%
Mkt Cap₹5K Cr
Compensation
To Be Published
Data being verified from audited reports
